Agenus News

Agenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the Compensation Committee of Agenus' Board of Directors granted

BusinesswireMay 24 17:00 ET

B.Riley Financial Maintains Agenus(AGEN.US) With Buy Rating, Maintains Target Price $42

B.Riley Financial analyst Mayank Mamtani maintains $Agenus(AGEN.US)$ with a buy rating, and maintains the target price at $42.According to TipRanks data, the analyst has a success rate of 26.2% and a

moomoo NewsMay 24 14:31 ET

Buy Rating Affirmed for Agenus Amid Promising Colorectal Cancer Study Results

TipRanksMay 24 13:55 ET

H.C. Wainwright Maintains Agenus(AGEN.US) With Buy Rating, Maintains Target Price $40

H.C. Wainwright analyst Emily Bodnar maintains $Agenus(AGEN.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 38.3% and a tota

moomoo NewsMay 24 06:35 ET

Analysts Offer Insights on Healthcare Companies: Agenus (AGEN), Merus (MRUS) and Iovance Biotherapeutics (IOVA)

TipRanksMay 24 06:20 ET

Agenus to Participate in Goldman Sachs 45th Annual Global Healthcare Conference

Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, and Robin Taylor, Chief Commercial

BusinesswireMay 23 07:30 ET

Express News | FDA Grants Agenus Type B End-of-Phase 2 Meeting to Discuss BOT/Bal Therapy for Relapsed or Refractory Metastatic Colorectal Cancer

ReutersMay 16 07:30 ET

Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy

Seeking AlphaMay 13 07:58 ET

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)

TipRanksMay 8 08:31 ET

Express News | HC Wainwright & Co. Reiterates Buy on Agenus, Maintains $40 Price Target

BenzingaMay 7 14:07 ET

Agenus Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/07/2024 229.49% HC Wainwright & Co. → $40 Reiterates Buy → Buy 03/18/2024 -58.81% B. Riley Securities $

BenzingaMay 7 14:06 ET

Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates

Ligand Pharmaceuticals (LGND) and Agenus (AGEN) said Tuesday they have signed a royalty financing agreement to support the clinical development of Agenus' botensilimab and balstilimab, including a con

MT NewswiresMay 7 12:24 ET

NanoViricides, TC BioPharm, Holdco Nuvo Among Healthcare Movers

Seeking AlphaMay 7 10:01 ET

Agenus Inc (AGEN) Q1 2024 Earnings: Misses Revenue and EPS Estimates Amid Strategic Developments

Yahoo FinanceMay 7 08:56 ET

Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M

07:50 AM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (AGEN) AGENUS Reports Q1 Revenue $28M

MT NewswiresMay 7 07:50 ET

Express News | Outside CRC, Agenus Expects To Release Updated Phase 1 And 2 Data In Melanoma, Lung Cancer, Sarcoma And Pancreatic Cancer Later This Year

BenzingaMay 7 07:41 ET

Express News | Agenus Q1 2024 GAAP EPS $(3.04) Beats $(3.14) Estimate, Sales $28.005M Miss $39.268M Estimate

BenzingaMay 7 07:40 ET

Express News | Agenus Inc - $100M Royalty Financing Agreement With Ligand Announced

ReutersMay 7 07:40 ET

Agenus Ended 1Q With a Cash and Cash Equivalent Balance of $52.9M >AGEN

Agenus Ended 1Q With a Cash and Cash Equivalent Balance of $52.9M >AGEN

Dow JonesMay 7 07:40 ET

Agenus 1Q Loss $63.5M >AGEN

Agenus 1Q Loss $63.5M >AGEN

Dow JonesMay 7 07:40 ET